VR Logo

LAVA Therapeutics N.V. (LVTX) download report


Healthcare | Biotechnology & Pharma Research

LAVA Therapeutics N.V. (LVTX) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments.

IPO Date: 25-Mar-2021

CEO, Pres & Exec. Director: Mr. Stephen Allen Hurly M.B.A., M.Sc.

VP of Fin.: Mr. Peter Ros

Listing: NASDAQ: LVTX

Country: Netherlands

Headquarters: Utrecht,

Website: https://www.lavatherapeutics.com

Key Facts

Market cap: $81.32 Mln

Revenue (TTM): $5.08 Mln

Earnings (TTM): $-35.23 Mln

Cash: $124.16 Mln

Total Debt: $5.10 Mln

Insider's Holding: 29.27%

Liquidity: Low

52 Week range: $2.28 - 11.13

Shares outstanding: 25,775,500

Stock Performance

Time Period LAVA Therapeutics N.V. (LVTX) S&P BSE Sensex S&P Small-Cap 600
YTD-46.91-7.86-19.79
1 month-5.50-3.75-9.59
3 months-32.87-10.80-13.28
1 Year-73.091.50-17.92
3 Years--10.755.46
5 Years--11.435.57
10 Years--11.849.48
As on 06-Jul-2022